Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Flecainide Acetate

FDA-approved product (tablet, oral), marketed as Flecainide Acetate, Tambocor.

Registered studies
7
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Flecainide Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiac arrhythmia
  • Ventricular arrhythmia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiarrhythmics, class ic
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli28.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

7registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Flecainide Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Flecainide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Flecainide in Idiopathic Premature Ventricular Contractions and Related Cardiomyopathy

    NCT06949748 · start 2024-04-26

    Registered record
    Registry ID
    NCT06949748
    Conditions
    Premature Ventricular Beats; Premature Ventricular Complexes; Premature Ventricular Contraction (PVC); Arrhythmia Ventricular; Ventricular Dysfunction, Left; Ventricular Dysfunction; Cardiomyopathies, Secondary; Cardiomyopathies
    Interventions
    Flecainide (monotherapy)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-04-26
    Completion
    2027-12-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremature Ventricular Beats; Premature Ventricular Complexes; Premature Ventricular Contraction (PVC); Arrhythmia Ventricular +4 more
    InterventionFlecainide (monotherapy)
    PhaseNot recorded
    Registry statusRecruiting

  • Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation

    NCT05039359 · start 2022-04-26

    Registered record
    Registry ID
    NCT05039359
    Conditions
    Paroxysmal Atrial Fibrillation
    Interventions
    FlecIH-103
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2022-04-26
    Completion
    2023-05-22
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Atrial Fibrillation
    InterventionFlecIH-103
    PhasePhase 3
    Registry statusTerminated

  • Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia

    NCT05213104 · start 2022-03-23

    Registered record
    Registry ID
    NCT05213104
    Conditions
    Patent Foramen Ovale; Atrial Arrhythmia; Cryptogenic Stroke
    Interventions
    Flecainide; Flecainide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2022-03-23
    Completion
    2026-09-11
    Enrolment
    186

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatent Foramen Ovale; Atrial Arrhythmia; Cryptogenic Stroke
    InterventionFlecainide; Flecainide
    PhasePhase 3
    Registry statusActive not recruiting

  • INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)

    NCT03539302 · start 2018-05-29

    Registered record
    Registry ID
    NCT03539302
    Conditions
    Paroxysmal Atrial Fibrillation (PAF)
    Interventions
    Flecainide Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-05-29
    Completion
    2022-01-17
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Atrial Fibrillation (PAF)
    InterventionFlecainide Acetate
    PhasePhase 2
    Registry statusCompleted

  • Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

    NCT01117454 · start 2011-12

    Registered record
    Registry ID
    NCT01117454
    Conditions
    Catecholaminergic Polymorphic Ventricular Tachycardia
    Interventions
    Flecainide Acetate; Placebo; Beta blocker
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-12
    Completion
    2015-12
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCatecholaminergic Polymorphic Ventricular Tachycardia
    InterventionFlecainide Acetate; Placebo; Beta blocker
    PhaseNot applicable
    Registry statusCompleted

  • To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation

    NCT00189319 · start 2003-09

    Registered record
    Registry ID
    NCT00189319
    Conditions
    Atrial Fibrillation
    Interventions
    Flecainide controlled release
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-09
    Completion
    Not recorded
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionFlecainide controlled release
    PhasePhase 4
    Registry statusCompleted

  • Flecainide in Treating Patients With Chronic Neuropathic Pain

    NCT00002996 · start 1998-05-04

    Registered record
    Registry ID
    NCT00002996
    Conditions
    Pain
    Interventions
    flecainide acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1998-05-04
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain
    Interventionflecainide acetate
    PhasePhase 2
    Registry statusCompleted